Loading …

EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation. The EVOLVE platform tackles the treatment challenges of cancer cell resistance to current immunotherapies. The company’s lead internal drug candidate, EVOLVE104, will enter the clinic in 2025. We are based in Branford, CT.
Annual Revenue$50M to $100M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.